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Abstract
Background: Widespread use of D-dimer in recent
years has led to the development of a number of new
fully automated quantitative D-dimer assays.
Methods: We evaluated the analytical performance of
the particle-enhanced immunoturbidimetric assay
Innovance D-DIMER (Siemens Medical Solutions) on
the Behring Coagulation System (BCS) analyzer.
Results: Within-run coefficients of variation (CVs) for
samples with low, borderline, slightly, and extremely
increased D-dimer concentrations were 2.1%–5.5%,
whereas between-run CVs for control samples with
low and extremely increased D-dimer were 5.5%–
8.4%. The assay exhibited good linearity in the work-
ing range between 0.17 mg/L and 5.45 mg/L fibrino-
gen equivalent units (FEU), with the lower limit of
detection of 0.099 mg/L FEU. The upper reference val-
ue determined in 40 plasma samples from healthy
volunteers was 0.495 mg/L FEU. The results obtained
in 457 fresh plasma samples were compared with
results obtained with VIDAS D-Dimer Exclusion. Pass-
ing and Bablok regression analysis demonstrated
highly significant correlation (ys1.370x–0.108,
rs0.952, p-0.001). Bland and Altman difference plots
demonstrated slightly higher results obtained with
Innovance D-DIMER that was more pronounced with
increasing values. Very good agreement between
both assays was observed (ks0.860; 95% confidence
interval (CI), 0.811–0.908).
Conclusions: This study demonstrates that Innovance
D-DIMER fulfills all analytical requirements for daily
routine use.
Clin Chem Lab Med 2009;47:945–51.
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Introduction
D-dimer is a stable terminal product of cross-linked
fibrin generated by plasmin degradation. As D-dimer
antigen is a specific indicator of fibrin formation, it is
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currently the most widely used laboratory marker for
in vivo coagulation activation (1).
Measurement of D-dimer concentrations has
gained widespread use in the diagnosis of various
clinical situations related to thrombosis and fibrinol-
ysis. It is especially useful as a diagnostic tool for
excluding suspected thromboembolic disease. Thus,
coagulation laboratories are faced with an increasing
number of requests for the determination of D-dimer.
Currently, more than 30 assays for the determina-
tion of D-dimer antigen are commercially available.
These assays are based on more than 20 different
D-dimer specific monoclonal antibodies that react
with conformational epitopes generated by factor
XIIIa-induced cross-linking on fibrin fragment D-dimer,
that are not present on fibrinogen fragment D, other
fibrinogen degradation products or native fibrinogen
(2). Several manufacturers have recently produced a
variety of new fully automated quantitative D-dimer
assays that are simple to perform and suitable for
individual and rapid testing. The majority of these
assays are latex-enhanced photometric immuno-
assays (LPIA) developed for the measurement of D-
dimer in plasma samples on coagulation analyzers,
that can be performed simultaneously with other
routine coagulation assays.
The aim of this study was to evaluate the analytical
performance of the recently developed particle-
enhanced immunoturbidimetric assay Innovance D-
DIMER on the Behring Coagulation System (BCS)
analyzer (Siemens Medical Solutions Diagnostics,
Deerfield, IL, USA).
Materials and methods
Principle of the D-dimer measurement
Innovance D-DIMER (Siemens Medical Solutions Diagnos-
tics, Deerfield, IL, USA) is a fully automated particle-
enhanced immunoturbidimetric assay for the quantitative
determination of D-dimer in plasma. The assay relies on the
8D3 monoclonal antibody, covalently coupled to polystyrene
particles, and is designed for performance on several auto-
mated coagulation analyzers from Siemens Medical Solu-
tions Diagnostics.
In this study, D-dimer testing was performed using the
BCS coagulation analyzer (Siemens Medical Solutions Diag-
nostics) with the Innovance D-DIMER Kit. The kit consists of
D-DIMER Reagent, D-DIMER Buffer, D-DIMER Supplement,
D-DIMER Diluent and D-DIMER Calibrator, according to the
manufacturer’s specifications. To a mixture of 9 mL of D-
DIMER Diluent and 9 mL of plasma, 72 mL of D-DIMER Buffer
and 27 mL of D-DIMER Supplement were added and incu-
bated at 378C for 180 s. The degree of agglutination was
measured after the addition of 72 mL of D-DIMER Reagent
(suspension of polystyrene particles covalently coated with
a monoclonal mouse antibody 8D3) as the decrease of trans-
mitted light at 570 nm caused by aggregates. The degree of
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agglutination was directly proportional to the concentration
of D-dimer in the sample and results were expressed in
mg/L fibrinogen equivalent units (FEU).
The measuring range of the assay is defined by the lot-
specific concentration of D-DIMER calibrator included in the
reagent kit. Concentrations range from ;0.19 mg/L to
4.40 mg/L FEU, which can be extended to ;35.20 mg/L FEU
by automatic redilution (1:8) of samples with results above
4.40 mg/L FEU. In addition to lot-specific concentrations,
each calibrator has a declared analyzer specific concentra-
tion of D-dimer.
In this study, a six-point calibration was performed auto-
matically by the instrument using the D-DIMER Calibrator
with a D-dimer concentration of 5.54 mg/L FEU declared for
BCS/BCS XP analyzers. Two calibration curves were pre-
pared: a lower one spanning 0.17–4.26 mg/L FEU, and a
higher one up to 34.09 mg/L FEU.
Evaluation samples
Two types of samples were used for the evaluation proce-
dure: consecutive patient samples submitted to the Clinical
Institute for Laboratory Diagnosis of the Clinical Hospital
Center Zagreb, Croatia for the determination of D-dimer, and
samples obtained from apparently healthy volunteers who
were members of the hospital staff.
Platelet-poor plasma was prepared by centrifugation at
2000 g for 15 min at room temperature of blood specimens
collected into siliconized glass tubes containing 0.105 mol/L
buffered sodium citrate (Becton Dickinson, Plymouth, UK) in
a ratio of nine parts of blood to one part anticoagulant. Fresh
plasma samples obtained within 2 h following collection
were used for the determination of the assay specific refer-
ence interval, precision and method comparison study. Com-
mercially available lyophilized plasma samples Innovance
D-DIMER Control: D-DIMER Control 1 (C1) for assessing the
lower measurement range, and D-DIMER Control 2 (C2) for
assessing the upper measurement range were used for qual-
ity control and for precision studies.
Four types of samples were used in the method compari-
son study: samples from healthy controls, plasma samples
from patients with a wide range of D-dimer concentrations,
lyophilized control samples (Innovance D-DIMER C1 and C2
from Siemens; VIDAS C1 and VIDAS C2 from bioMérieux,
Marcy l’Étoile, France), calibrators (Innovance D-DIMER
Calibrator from Siemens and VIDAS S1, VIDAS S2 from
bioMérieux), and six lyophilized citrated plasma samples
kindly supplied by the UK National External Quality Assess-
ment Scheme (UK NEQAS) for blood coagulation.
Evaluation procedure
The evaluation procedure included determination of within-
run and between-run precision, accuracy, linearity and lower
limit of detection, verification of the assay-specific reference
interval and method comparison studies.
Within-run precision was determined using three fresh
plasma samples with different D-dimer concentrations:
sample 1 (low D-dimer), sample 2 (borderline D-dimer) and
sample 3 (slightly increased D-dimer), and control plasma
sample Innovance D-DIMER C2 (extremely increased D-
dimer). For each sample, 20 replicates were analyzed in the
single analytical run.
Between-run precision was assessed using two control
plasma samples (Innovance D-DIMER C1 and C2). Samples
were analyzed over 20 consecutive days with duplicate
determinations performed in the morning (samples A) and
in the afternoon (samples B) on each day. Within- and
between-run precision was determined using the same
calibration curve.
Accuracy was evaluated by calculating the bias from the
target value for control plasma samples.
Linearity was evaluated by analysis of multiple dilutions
of a patient sample with increased D-dimer concentrations
(5.45 mg/L FEU) using the original calibration curve. Seven
dilutions were prepared using Innovance D-DIMER Diluent at
fixed ratios of 4:5, 3:4, 1:2, 1:4, 1:8, 1:16 and 1:32. Each dilu-
tion was assayed in duplicate and percent recovery was cal-
culated from the measured mean values for each dilution.
The lower limit of detection of the assay was determined
by measurement of D-dimer concentrations in a sample
without D-dimer (Innovance D-DIMER DILUENT) and calcu-
lated as the mean valueq3 SD (3).
Assay-specific reference intervals were verified by meas-
urement of D-dimer concentrations in citrated blood samples
obtained from 40 apparently healthy volunteers (members
of the hospital staff) who had no known defects of blood
coagulation.
For method comparison studies, samples were tested in
parallel with Innovance D-DIMER vs. the routine assay nor-
mally used in our laboratory: the VIDAS D-Dimer Exclusion
on the mini VIDAS Immunoassay system (bioMérieux, Marcy
l’Étoile, France). The principle of the VIDAS D-Dimer Exclu-
sion assay utilizes a two-step enzyme immunoassay sand-
wich method using two different monoclonal antibodies
(10B5E12C9 and 2C5A10) and fluorescent detection (4).
Results are reported in mg/L FEU, with a measurement range
from 0.05 mg/L to 10.0 mg/L FEU. Both D-dimer methods
were performed according to the manufacturer’s recommen-
dations and the same cut-off value (-0.5 mg/L FEU) was
used for both assays.
Statistical analysis
The MedCalc program version 9.3.2.0 for Windows (MedCalc
Software, Mariakerke, Belgium) was used for statistical anal-
ysis. Correlation between methods was calculated according
to Spearman and regression analysis was performed using
the method of Passing and Bablok (5). The 95% confidence
intervals (CIs) were calculated according to binomial distri-
bution. The agreement between results was evaluated
according to Bland and Altman (6). Overall agreement
between both assays in their diagnostic classification was
estimated by calculation of the kappa coefficient (k) for
agreement (7), and the obtained value was evaluated accord-
ing to Landis and Koch (8).
Results
Within-run and between-run precision
Results of within-run and between-run precision stud-
ies are shown in Table 1. The within-run coefficients
of variation (CVs) ranged from 2.1% for the control
sample with extremely increased D-dimer concentra-
tions to 5.5% for the patient sample with low D-dimer
concentrations. The between-run CVs ranged from
5.5% to 8.4%, with slightly higher CVs obtained in the
morning run compared to CVs obtained in the after-
noon run, for both control samples.
For the study on accuracy, the bias from the target
values for the commercial control samples, Innovance
D-DIMER C1 and C2, were 7.7% and 7.3%,
respectively.
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Table 1 Within-run and between-run precision of the Innovance D-DIMER assay.
n Mean"SD, Range, CV, %
mg/L FEU mg/L FEU
Within-run
Sample 1 20 0.31"0.02 0.29–0.35 5.5
Sample 2 20 0.50"0.01 0.47–0.52 2.6
Sample 3 20 0.81"0.04 0.71–0.85 4.5
Innovance D-DIMER Control 2 20 3.02"0.06 2.89–3.10 2.1
Between-run*
Innovance D-DIMER Control 1
A 20 0.37"0.03 0.33–0.45 8.4
B 20 0.35"0.02 0.32–0.41 7.1
Innovance D-DIMER Control 2
A 20 3.18"0.20 2.78–3.43 6.2
B 20 3.00"0.17 2.68–3.25 5.5
*Innovance D-DIMER Control 1 and 2 were measured in the morning (run A) and in the afternoon (run B) of each day. SD,
standard deviation; FEU, fibrinogen equivalent units; CV, coefficient of variation.
Table 2 Determination of linearity of the Innovance D-DIMER assay on the BCS analyzer using multiple dilutions of a patient
sample with increased D-Dimer concentrations.
Dilution Measured mean value Expected value, Recovery,
Ratio % mE/min mg/L FEU
mg/L FEU %
1:1 100 577.7 4.99 5.45 91.6
4:5 80 507.0 4.29 4.36 98.4
3:4 75 493.3 4.17 4.09 102.0
1:2 50 338.7 2.86 2.72 105.1
1:4 25 145.7 1.42 1.36 104.4
1:8 12.5 67.79 0.74 0.68 108.8
1:16 6.25 32.16 0.32 0.34 94.1
1:32 3.125 19.98 0.15 0.17 88.2
FEU, fibrinogen equivalent units.
Linearity and lower limit of detection
The results obtained for the linearity study are shown
in Table 2. The mean recovery was 99.1%, ranging
from 88.2% to 108.8%. The correlation coefficient for
linear regression analysis comparing measured and
expected D-dimer concentrations was r2s0.995, with
a regression line ys0.949xq0.068. These results indi-
cate that the assay exhibited very good linearity in the
working range of 0.17–5.45 mg/L FEU, which is even
greater than the measuring range stated from the
manufacturer.
The lower limit of detection was 0.099 mg/L FEU.
Reference interval
The median D-dimer concentration was 0.27 mg/L
FEU and the highest measured concentration was
0.55 mg/L FEU. The upper reference limit based on
the 95th percentile was 0.495 mg/L FEU.
Method comparison
A total of 457 fresh plasma samples (40 plasma sam-
ples from healthy controls and 417 plasma samples
from inpatients and outpatients) were analyzed using
both assays. For statistical analysis, 38 samples with
results outside the measurement range were
excluded.
Linear regression analysis according to Passing and
Bablok (Figure 1) showed significant correlation
(p-0.001). Better correlation (rs0.930) was obtained
for samples with values up to 4.26 mg/L FEU (undi-
luted samples), compared to a correlation coefficient
of 0.748 for samples with concentrations )4.26 mg/L
FEU, and obtained following automatic dilution.
The results obtained with both assays were also
evaluated according to the method of Bland and
Altman. The analysis included absolute difference
plots, percent difference plots and ratio difference
plots. These analyses were performed for all samples,
and separately for undiluted, and diluted samples.
Percent difference plots and ratio difference plots are
shown in Figure 2. Mean absolute difference between
Innovance D-DIMER and VIDAS D-Dimer Exclusion
was 0.8 mg/L FEU for all samples that were tested, 0.2
mg/L FEU for undiluted samples and 4.8 mg/L FEU
for diluted samples.
Agreement between methods, defined as the per-
centage of values found concomitantly positive or
negative between Innovance D-DIMER and VIDAS D-
Dimer Exclusion, was 94.3%. Concordance between
results was observed in 96.5% of samples with results
above the cut-off value and in 97.8% of samples
below the cut-off value. If we assumed the Vidas to
be the gold standard, sensitivity was 96.1%, specific-
ity 89.1%, negative predictive value 93.4%, and the
positive predictive value 93.5%. The obtained k was
0.860 (95% CI, 0.811–0.908).
The results obtained for commercial D-dimer con-
trol samples and calibration plasma samples from
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Figure 1 Method comparison between Innovance D-DIMER and VIDAS D-Dimer Exclusion according to Passing and Bablok.
All tested samples (A), undiluted samples (B) and diluted samples (C).
both manufacturers are shown in Table 3. Values
were ;3-fold higher for VIDAS control samples and
calibrators measured with the Innovance D-DIMER
method.
Method comparison results for UK NEQAS plasma
samples are summarized in Table 4. Increased values
were observed for all samples with Innovance D-
DIMER. Ratios ranged from 1.22 to 1.51, except for
one sample where similar D-dimer concentrations
were measured with both assays.
Discussion
In recent years, a growing number of quantitative D-
dimer assays have been developed for use in routine
laboratory practice. The majority of these assays are
fully automated LPIA that can be performed using dif-
ferent coagulation analyzers and simultaneously with
other routine coagulation assays. Every new assay
needs to be validated in terms of its analytical and
clinical performance prior to implementation for daily
use. Thus, the data from this study summarize the
analytical performance of the Innovance D-DIMER
assay on the BCS coagulation analyzer.
Innovance D-DIMER shares the same characteristics
of other LPIA D-dimer assays. The method is fully
automated, uses a small amount of sample per test
(9 mL) and has a short sample turnaround time of
10 min. The assay displayed very good linearity, up
to 5.45 mg/L FEU, that was greater than the measure-
ment range stated by the manufacturer. A possible
reason for this could be differences in the composi-
tion of the mixture of D-dimer-containing fragments
in the calibrator and samples used for the assessment
of linearity (1, 9), although the calibrator and samples
were both of human origin. The wide linear range
offers the advantage of direct measurement of the
majority of samples (88.2%), without the need for
dilution and thus decreased turnaround time.
Although the wide measurement range provides
several benefits, one limitation is the usually high CV
at low concentrations (9), which was reproducible in
the present study. However, assay reproducibility at
concentrations near the cut-off value that represent
the critical point of the assay, as stressed by Reber
and de Moerloose (9), was very low (CVs2.6%).
The lower limit of detection of the assay was almost
two-fold lower than the lowest calibrator value
(0.099 mg/L FEU). We were able to measure D-dimer
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Figure 2 Method comparison between Innovance D-DIMER and VIDAS D-Dimer Exclusion according to Bland and Altman.
Percent difference plot (A) and ratio difference plot (B) for all samples, percent difference plot (C) and ratio difference plot (D)
for undiluted samples, percent difference plot (E) and ratio difference plot (F) for diluted samples.
concentrations that were below the lowest point of
the calibration curve (-0.17 mg/L FEU).
Method comparison studies were performed using
the currently proposed D-dimer reference method,
VIDAS D-Dimer Exclusion (10). In contrast to the
majority of evaluation studies, we measured D-dimer
using fresh plasma samples with both assays in order
to exclude the potential effects of freezing on sample
stability. In addition, the comparison of results that
were obtained was simplified because results for both
assays were expressed in the same units (mg/L FEU)
and the same recommended cut-off value (-0.5
mg/L FEU) was used. Excellent correlation between
Innovance D-Dimer assay and VIDAS D-Dimer Exclu-
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Table 3 Results of commercial D-Dimer control samples and calibration plasma samples obtained with D-Dimer assays.
D-Dimer control/calibration plasma Lot Assigned value and VIDAS Innovance
number confidence interval, D-Dimer D-DIMER,
mg/L FEU Exclusion, mg/L FEU
mg/L FEU
Control plasma
VIDAS C1 080509-0 4.72 (3.30–6.14) 5.05 15.86
VIDAS C2 080509-0 0.53 (0.40–0.65) 0.51 1.70
Innovance D-DIMER Control 1 560710 0.39 (0.31–0.47) 0.25 0.35
Innovance D-DIMER Control 2 560710 2.88 (2.30–3.46) 1.08 2.96
Calibration plasma
VIDAS S1 080509-0 4.63 – 15.18
VIDAS S2 080509-0 0.46 – 1.37
Innovance D-DIMER Calibrator 560510 5.54 2.35 –
FEU, fibrinogen equivalent units.
Table 4 Results of UK NEQAS plasma samples obtained with both D-Dimer assays.
UK NEQAS Innovance VIDAS D-Dimer Ratio of Innovance
sample D-DIMER, Exclusion, D-DIMER and VIDAS
mg/L FEU mg/L FEU D-Dimer Exclusion
DD2006/1 3.69 2.44 1.51
DD2006/2 1.93 1.40 1.38
DD2006/3 1.13 0.78 1.45
DD2006/4 1.49 1.49 1.00
DD2006/5 1.32 1.08 1.22
07/35 2.11 1.71 1.23
UK NEQAS, UK National External Quality Assessment Scheme; FEU, fibrinogen equivalent units.
sion was obtained which was even better than the
correlation obtained between both assays using the
same analyzers described for a recent multicenter
evaluation study by de Moerloose et al. (11). How-
ever, the results obtained in this study showed slight-
ly higher results with Innovance D-DIMER that were
more pronounced with increasing values as readily
demonstrated by the Bland-Altman difference plots.
Finally, as shown by the k coefficient in the method
comparison study, very good agreement was found
between the two methods.
Our results corroborate the previously published
statement that a simple conversion factor between
two assays cannot be applied to the entire concentra-
tion range since this can lead to discrepant results at
both low and high measured values (1).
The 3-fold higher values obtained using VIDAS con-
trol samples measured with the Innovance D-DIMER
is a consequence of the same difference observed
when comparing assay-specific calibrators despite
their being of the same origin (human). This is why
manufacturers provide calibrators and control sam-
ples that are valid only for the assay for which they
are designed (9).
For routine clinical use, assays for D-dimer must
fulfill several criteria (12). This study shows that Inno-
vance D-DIMER assay fulfills all the characteristics
needed concerning ease of use and automated per-
formance, short turnaround time of 10 min, reliable
measurement of values close to the cut-off value,
assay availability of 24 h a day, even for single sam-
ples, and wide measurement range. In addition, the
assay that was clinically validated in a recently pub-
lished multicenter evaluation study by de Moerloose
et al. (11) proved to be accurate when used for the
diagnostic work-up of outpatients with venous
thromboembolism.
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